[{"id":"668fd5a3-2595-4b5e-9008-d986e7e3501e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05078866","created_at":"2021-10-15T15:53:08.571Z","updated_at":"2025-02-25T13:40:39.704Z","phase":"Phase 1/2","brief_title":"Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients","source_id_and_acronym":"NCT05078866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOUS-209"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-21"},{"id":"9fe2be17-9d81-4e3d-988f-0f2821f38ab8","acronym":"KEYNOTE-E58","url":"https://clinicaltrials.gov/study/NCT04041310","created_at":"2021-01-18T19:49:29.596Z","updated_at":"2025-02-25T16:09:21.987Z","phase":"Phase 1/2","brief_title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","source_id_and_acronym":"NCT04041310 - KEYNOTE-E58","lead_sponsor":"Nouscom SRL","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NOUS-209"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-11-20"}]